INPP4B

Across TCGA pan-cancer cohorts, INPP4B Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated INPP4B data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher INPP4B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated INPP4B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

DLBC, MESO, and PAAD are the cancer types where INPP4B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	24	view →
MESO	OS	Median	II,III,IV	0.071	0.572	<.001	24	view →
PAAD	OS	Median	All	0.028	0.614	<.001	24	view →
SCLC	OS	Median	III,IV	0.082	0.639	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.912	0.617	.019	6	view →
LIHC	DFS	Median	All	0.349	0.559	.023	5	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

INPP4B–DLBC (OS)

Open the DLBC breakdown →